Mind over matter - the expert view on CNS
This article was originally published in Scrip
Executive Summary
The CNS field is a $100 billion market, and with ageing populations and unmet needs, the segment is set to grow even further. We spoke to Ben Greener, Datamonitor's head of CNS market analysis, about the likely path of CNS drugs and what companies need to consider when building their pipelines.